Atara Biotherapeutics (ATRA) Non-Current Assets (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Non-Current Assets came in at $7.8 million in Q1 2026, down 77.55% YoY from $34.9 million in Q1 2025, and down 2.48% on a QoQ basis from $8.0 million in Q4 2025.
Atara Biotherapeutics (ATRA) Non-Current Assets (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Non-Current Assets data on file, last reported at $7.8 million in Q1 2026.
- Quarterly Non-Current Assets fell 77.55% year-over-year to $7.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.7 million (down 78.51% YoY) and the FY2025 annual result came in at $8.0 million, down 81.85% from the prior year.
- Non-Current Assets declined to $7.8 million in Q1 2026, from $8.0 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $89.1 million in Q2 2022 to a low of $7.8 million in Q1 2026.
- A 5-year average of $53.4 million and a median of $58.8 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 38.27% — and 2025, when it tumbled 81.85%.
- Tracing ATRA's Non-Current Assets over 5 years: stood at $81.3 million in 2022, then declined by 21.77% to $63.6 million in 2023, then tumbled by 30.54% to $44.2 million in 2024, then plunged by 81.85% to $8.0 million in 2025, then retreated by 2.48% to $7.8 million in 2026.
- The last three Non-Current Assets figures came in at $7.8 million (Q1 2026), $8.0 million (Q4 2025), and $11.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 18.06 Bn |
| 10 | Atara Biotherapeutics | 142.36 Mn | 125.81 Mn | 439,000.00 | 7.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.49 Mn |
| Mar 31, 2026 | 7.82 Mn |
| Dec 31, 2025 | 8.02 Mn |
| Sep 30, 2025 | 11.74 Mn |
| Jun 30, 2025 | 12.13 Mn |
| Mar 31, 2025 | 34.86 Mn |
| Dec 31, 2024 | 44.20 Mn |
| Sep 30, 2024 | 50.85 Mn |
| Jun 30, 2024 | 54.87 Mn |
| Mar 31, 2024 | 58.84 Mn |
| Dec 31, 2023 | 63.64 Mn |
| Sep 30, 2023 | 70.09 Mn |
| Jun 30, 2023 | 74.12 Mn |
| Mar 31, 2023 | 77.90 Mn |
| Dec 31, 2022 | 81.34 Mn |
| Sep 30, 2022 | 85.27 Mn |
| Jun 30, 2022 | 89.14 Mn |
| Mar 31, 2022 | 82.89 Mn |
| Dec 31, 2021 | 83.51 Mn |
| Sep 30, 2021 | 80.43 Mn |